ERBB2 and non-small cell lung carcinoma: In a phase II DESTINY-Lung01 trial of HER2-mutant NSCLC refractory to standard treatment, T-DXd (6.4 mg/kg) demonstrated an ORR of 55% with a DOR of 9.3 months, PFS of 8.2 months and OS of 17.8 months [78].